| Title |
The promising alliance of anti-cancer electrochemotherapy with immunotherapy
|
|---|---|
| Published in |
Cancer and Metastasis Reviews, March 2016
|
| DOI | 10.1007/s10555-016-9615-3 |
| Pubmed ID | |
| Authors |
Christophe Y. Calvet, Lluis M. Mir |
| Abstract |
Anti-tumor electrochemotherapy, which consists in increasing anti-cancer drug uptake by means of electroporation, is now implanted in about 140 cancer treatment centers in Europe. Its use is supported by the English National Institute for Health and Care Excellence for the palliative treatment of skin metastases, and about 13,000 cancer patients were treated by this technology by the end of 2015. Efforts are now focused on turning this local anti-tumor treatment into a systemic one. Electrogenetherapy, that is the electroporation-mediated transfer of therapeutic genes, is currently under clinical evaluation and has brought excitement to enlarge the anti-cancer armamentarium. Among the promising electrogenetherapy strategies, DNA vaccination and cytokine-based immunotherapy aim at stimulating anti-tumor immunity. We review here the interests and state of development of both electrochemotherapy and electrogenetherapy. We then emphasize the potent beneficial outcome of the combination of electrochemotherapy with immunotherapy, such as immune checkpoint inhibitors or strategies based on electrogenetherapy, to simultaneously achieve excellent local debulking anti-tumor responses and systemic anti-metastatic effects. |
Mendeley readers
The data shown below were compiled from readership statistics for 138 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 1% |
| Germany | 2 | 1% |
| United Kingdom | 1 | <1% |
| France | 1 | <1% |
| Unknown | 132 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 27 | 20% |
| Researcher | 17 | 12% |
| Student > Bachelor | 17 | 12% |
| Student > Master | 16 | 12% |
| Student > Doctoral Student | 8 | 6% |
| Other | 23 | 17% |
| Unknown | 30 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 32 | 23% |
| Biochemistry, Genetics and Molecular Biology | 25 | 18% |
| Engineering | 13 | 9% |
| Veterinary Science and Veterinary Medicine | 8 | 6% |
| Agricultural and Biological Sciences | 6 | 4% |
| Other | 23 | 17% |
| Unknown | 31 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 November 2021.
All research outputs
#7,890,886
of 23,923,788 outputs
Outputs from Cancer and Metastasis Reviews
#300
of 835 outputs
Outputs of similar age
#109,241
of 304,023 outputs
Outputs of similar age from Cancer and Metastasis Reviews
#3
of 7 outputs
Altmetric has tracked 23,923,788 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 835 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.3. This one is in the 33rd percentile – i.e., 33% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 304,023 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 55% of its contemporaries.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than 4 of them.